Send to

Choose Destination
Ther Drug Monit. 2017 Aug;39(4):305-307. doi: 10.1097/FTD.0000000000000397.

Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.

Author information

*Department of Clinical and Biological Pharmacology and Pharmacovigilance, Rennes University Hospital, Pharmacoepidemiology and Drug Information Center; †Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University; ‡Inserm, CIC-P 1414 Clinical Investigation Center; and §Liver Disease Unit, Rennes University Hospital, Rennes, France.


No drug-drug interaction study has been conducted to date for the combination of ombitasvir, paritaprevir/ritonavir, dasabuvir (3D), and mycophenolic acid (MPA). We here report the case of a hepatitis C virus-infected patient treated with 3D and MPA for vasculitis. In light of the threat of drug-drug interaction, the concentration of MPA was measured before, during, and 15 days after the end of the 3D treatment. Similar values were found at all 3 time points, thus indicating that there is probably no need to adapt MPA dosage to 3D.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center